Biocon (NSE:BIOCON) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BIOCON Biocon Ltd NSE:BIOCON
89 GF Score
Price ₹437.20
GF Value ₹339.48
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Biocon FFO?

FFO (Funds from operations) only applies to REITs.

NSE:BIOCON
89GF Score
Biocon Ltd NSE:BIOCON
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biocon (NSE:BIOCON) Overvalued in 2026?

Based on GuruFocus' analysis, Biocon stock appears to be overvalued. The current stock price of ₹437.20 is trading 28.8% above its estimated GF Value™ of ₹339.48. GuruFocus considers Biocon to be Modestly Overvalued.

Key valuation signals for NSE:BIOCON:

  • FFO:
  • GF Value™: ₹339.48 vs. price of ₹437.20 (28.8% above fair value)
  • GF Score™: 89/100 with 10 warning signs

No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocon Business Description

Other Exchanges 532523:India
Address 20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
89GF Score

Get the complete analysis for NSE:BIOCON

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹437.20
Price
₹339.48
GF Value